Smoking, obesity, diabetes, and blood pressure are all longitudinally associated with changes to retinal vessel traits.

A monitoring protocol can detect intraocular inflammation early and enable favorable visual outcomes in patients being treated for AMD.

Intravitreal aflibercept 2 mg regimen is linked with long-term visual acuity improvements in macular edema following CRVO.